Kalorama Information, along with representatives from parent company Science and Medicine Group, will be present at the Association for Molecular Pathology (AMP) meeting in Baltimore Maryland. We will be covering the meeting for Lab Pulse.com, Kalorama Information and Instrument Business Outlook. Seminars of particular interest to Kalorama Information: Practical Approaches to Centralizing (or Decentralizing) Molecular […]
The global volume of in vitro diagnostic (IVD) procedures has reached over 68 billion and is forecast to increase 3.4% annually to 81.0 billion in 2024, according to Kalorama’s new report on procedure volumes. These statistics are important for business planning, particularly for new products. The same timeframe will see worldwide sales of IVD products […]
This is a positive development for next-generation sequencing’s clinical future, not only in diagnostic assessment of disease but also in therapy selection. But this is still about future development, and we’ll watch the products that the collaboration produces. We’ll also watch what the competition does — partnerships oft beget other partnerships.” KALORAMA as quoted in […]
Announcing a new product from Kalorama Information, Part of the Science and Medicine Group. The Kalorama Clinical Masterfile. For the best business results, clinical diagnostics marketers need knowledge about several elements: What products do my customers currently have? What types of products? Clinical Chemistry, Micro, Molecular, Immunoassays, Hematology? How old are those systems? Is it […]
Kalorama Information, a part of Science and Medicine Group, has announced that it has published its 25th report since the acquisition of the company by Science and Medicine Group. Since November, the firm has reported on food safety testing, infectious disease, Latin American Markets, molecular diagnostics and many other markets. “Experts in sequencing, liquid biopsy, […]
As reported on LabPulse.com (Sign up at http:www.labpulse.com) — Providers of proficiency testing for CLIA tests are becoming increasingly concerned about the lack of external quality control and oversight of CLIA-waived test kits, as the number of waived kits continues to expand. Some 1,400 waived test kits are now on the market, compared with 30 […]
Quidel is the market leader in point-of-care (POC) cardiac markers, according to a recent report from Kalorama Information. Abbott, Roche and Siemens Healthineers and Response Biomedical also are among the top companies. The findings were reported in Kalorama Information’s latest report, Worldwide Market for Point-of-Care (POC) Diagnostics. Quidel is a market leader in rapid immunoassays and […]
There has been a milestone reached in 2019, but not one to celebrate. There are now more cases of measles in the United States than any time since 1992. 1,077 individual measles cases were confirmed as of June 2019, according to the Centers for Disease Control and Prevention (CDC). With doctors less familiar than they […]
News of an approval of a biosimilar for a major Roche cancer drug is, we think, evidence that U.S. biosimilars are a growth market opportunity. At the same time, the approval is a growth limiter for booming cancer drug markets. Pfizer Inc confirmed Friday that the the FDA approved its biosimilar to Avastin. Pfizer’s Zirabev […]
The 67th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, held recently in Atlanta, Georgia, is a major showcase for mass spectrometry system (MS) introductions. Below are some of the trends evident among the many system launches. Small is Big Agilent Technologies introduced the LC/MSD iQ single quadrupole MS, measuring 12 x 18.7 in (305 […]
